A novel dual biologic regimen combining dazodalibep and belatacept is well tolerated and could enable more than half the kidney transplant recipients to avoid broader metabolic pathway inhibitors.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/dual-biologics-may-end-daily-pills-post-kidney-transplant-2026a10003t9?src=rss
Author :
Publish date : 2026-02-06 10:46:00
Copyright for syndicated content belongs to the linked Source.